Karyopharm Therapeutics (KPTI) Misses Q2 EPS by 432c
Tweet
Share
E-mailGet Alerts KPTI Hot Sheet
Join SI Premium – FREE
Karyopharm Therapeutics (NASDAQ: KPTI) reported Q2 EPS of ($4.32). Revenue for the quarter came in at $37.93 million.
For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple announced foldable iPhone Duo, starting at $1,999
- Apple announces AirPods 5
- Anthropic: identified a fourth incident, from January 2026, involving an early version of Claude Opus 4.6. We have notified all affected parties
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
